A Phase 2 trial of OK-101 will begin soon as the company…
Studying modified RNA messages may help treat disease and develop new therapeutics…
Studies with candidate VLA15 have been discontinued at certain sites Pfizer has…
AbbVie announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA)…
Ipsen has made significant strides in its long-standing effort to bring palovarotene to market for…
Global preclinical programs hold potential for disease-modifying therapies Pheno Therapeutics (Pheno) –…
Pharmaforum is proud to announce the first-ever Disease-Free Global Summit. This is his two-day event…
Takeda announces positive results from a Phase 3 trial of TAK-755, an experimental treatment for…
Partnership supports development of new algorithms to identify at-risk patients Anumana, an…
A new initiative to advance research and development in rare and pediatric diseases was launched…
Copyright ©️ All rights reserved. | Investors Radar
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
